Print
Email
Print Edition Stories
MHT's Emerging Technologies Forum: Health IT and the Cloud
MHT's Julie Donnelly: Biotechs lag in social media use
Burlington-based medical device firm InfraReDx Inc. has completed a $21 million equity funding, intended for the commercial launch of its LipiScan IVUS Coronary Imaging System.
The financing was backed by both new and returning investors, though the company names only Sanderling Ventures.
The LipiScan system is referred to by InfraReDx officials as “the world’s first and only intravascular imaging system” that combines intravascular ultrasound (IVUS) and near infrared (NIR) technology. Its NIR spectroscopy identifies the chemical content of the plaque, while the intravascular ultrasound gives doctors and image of the plaque and stent.
The LipiScan systems is intended for commercial availability in Europe next year and has already been granted marketing clearance in the U.S. from the Food and Drug Administration.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
